NEXTBIOMEDICAL Co., Ltd.
Financials
Valuation Metrics
NEXTBIOMEDICAL Co., Ltd.'s Market Cap is ₩2392B. At end of 2025 it was ₩7400B. Ranked #759 of 2,421 in KR market (top 31%), #337 of 1,640 on KOSDAQ (top 21%), #21 of 96 in Health Care Equipment & Services (top 22%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 239.21B KRW | KR#759/2,421 Sec#21/96 |
| Revenue | 17.79B KRW | KR#2,173/2,421 Sec#72/96 |
| Net Income | 232.6M KRW | KR#1,533/2,421 Sec#49/96 |
| Total Assets | 59.27B KRW | KR#2,115/2,421 Sec#69/96 |
| Net Assets | 48.11B KRW | KR#1,933/2,421 Sec#61/96 |
| Employees | 72 | KR#1,861/2,421 Sec#74/96 |
| Value | ||
| P/E | 1028.61x | KR#1,548/2,421 Sec#49/96 |
| P/B | 4.97x | KR#2,242/2,421 Sec#89/96 |
| P/S | 13.45x | KR#2,305/2,421 Sec#89/96 |
| FCF Yield | -0.79% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | 0.48% | KR#1,516/2,421 Sec#49/96 |
| ROA | 0.39% | KR#1,498/2,421 Sec#49/96 |
| Op. Margin | -12.92% | KR#2,041/2,421 Sec#66/96 |
| Revenue Growth | 72.67% | KR#131/2,421 Sec#10/96 |
| Earnings Growth | -107.41% | KR#1,160/2,421 Sec#40/96 |
| Financial Health | ||
| Debt Ratio | 23.19% | KR#449/2,421 Sec#25/96 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/96 |
| FCF | -1.90B KRW | KR#1,333/2,421 Sec#41/96 |
| Cash | 6.79B KRW | KR#1,890/2,421 Sec#63/96 |
| Current Ratio | 5.02x | KR#286/2,421 Sec#24/96 |
| Performance | ||
| 1Y Return | -60.95% | KR#2,214/2,421 Sec#83/96 |
| 1M Return | -12.69% | KR#2,187/2,421 Sec#83/96 |
| From 52W High | -71.39% | KR#2,220/2,421 Sec#85/96 |
| 1Y MDD | -70.51% | KR#2,014/2,421 Sec#75/96 |
| Trading | ||
| Volume | 14,891 shares | KR#1,740/2,421 Sec#69/96 |
| Trading Value | 433.0M KRW | KR#978/2,421 Sec#32/96 |
| Foreign Own. | 2.20% | KR#1,556/2,421 Sec#57/96 |
| Per Share | ||
| EPS | 28 KRW | KR#1,531/2,421 Sec#49/96 |
| BPS | 5,812 KRW | KR#1,378/2,421 Sec#34/96 |
Company Info
Established in 2014, NEXT BIOMEDICAL is an innovative bio-solution company specially listed on the KOSDAQ market as a technology growth company in 2024. Leveraging polymer and drug delivery system technologies, the company develops products like hemostatic agents for endoscopy and vascular embolization microspheres, earning recognition for its technological prowess and innovation through FDA and CE certifications. It is pursuing the establishment of global distribution networks and sales channels by signing distribution rights agreements in the US, Europe, and Japan through partnerships with global medical device companies. NEXT BIOMEDICAL was established in 2014 and is headquartered in Yeonsu-gu, Incheon.